Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 6/20 | 0.46 |
| ▸ | EIF4E | P06730 | 7/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832584 | 0.89 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1KMO | |
| SCHEMBL831794 | 0.87 | KMO (0.43) | ALDH1A1L3MBTL1KMOEIF4ETTR | |
| SCHEMBL831092 | 0.86 | KMO (0.42) | ALDH1A1L3MBTL1KMOEIF4ETTR | |
| SCHEMBL830425 | 0.85 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1 | |
| SCHEMBL829626 | 0.83 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1KMOAKR1C3AKR1C2 | |
| SCHEMBL830844 | 0.81 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1KMO | |
| SCHEMBL831894 | 0.79 | KMO (0.43) | ALDH1A1L3MBTL1KMO | |
| SCHEMBL831698 | 0.79 | KMO (0.43) | ALDH1A1L3MBTL1KMO | |
| SCHEMBL829557 | 0.77 | XDH (0.45) | ALDH1A1L3MBTL1KMO | |
| SCHEMBL832846 | 0.76 | MAPT (0.43) | ALDH1A1L3MBTL1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2009033561-A1 | SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | SLC5A6, FABP3, NAPRT | ALDH1A1 1238/4885L3MBTL1 823/4885KMO 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.